Dr Barrie Thorpe, Executive Vice President of Operations for AstraZeneca PLC said: "This investment is critical to ensure unconstrained supply of both 'Casodex' and 'Zomig'. To maintain our competitive edge we must ensure that leading edge technology is used in our manufacturing facilities. This investment will help us update existing equipment at Plankstadt and forms part of our global operations strategy."

AstraZeneca have set challenging growth targets for the business and the success of both 'Zomig' and 'Casodex' will be essential to their achievement.